Advances in cellular senescence in idiopathic pulmonary fibrosis (Review)

Shan Han; Qiangwei Lu; Xiaoqiu Liu

doi:10.3892/etm.2023.11844

Advances in cellular senescence in idiopathic pulmonary fibrosis (Review)

Exp Ther Med. 2023 Feb 15;25(4):145. doi: 10.3892/etm.2023.11844. eCollection 2023 Apr.

Authors

Shan Han^{1

2}, Qiangwei Lu¹, Xiaoqiu Liu¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin 130000, P.R. China.
² Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi 712000, P.R. China.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and fatal interstitial lung disease of unknown cause, with a median survival of 2-3 years. Its pathogenesis is unclear and there is currently no effective treatment for IPF. Approximately two-thirds of patients with IPF are >60 years old, with a mean age of 66 years, suggesting a link between aging and IPF. However, the mechanism by which aging promotes development of PF remains unclear. Senescence of alveolar epithelial cells and lung fibroblasts (LFs) and their senescence-associated secretion phenotype (SASP) may be involved in the occurrence and development of IPF. The present review focus on senescence of LFs and epithelial and stem cells, as well as SASP, the activation of profibrotic signaling pathways and potential treatments for pathogenesis of IPF.

Keywords: cellular senescence; epithelial cell; idiopathic pulmonary fibrosis; lung fibroblast; senescence-associated secretion phenotype; treatment.

Publication types

Review

Grants and funding

Funding: The present study was supported by the Natural Science Foundation of Jilin Science and Technology Department (grant no. 20160101089JC) and the Health and Family Planning Research Project of Jilin Province (grant no. 20152020).